Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (CRVS) reported a net loss of $9.8 million for Q3 2020, improving from $11.0 million in Q3 2019. Cash reserves decreased to $51.4 million from $78.0 million at year-end 2019. R&D expenses fell to $6.6 million, while G&A expenses rose to $3.2 million. Key developments include upcoming FDA meetings for ciforadenant in renal cell cancer and promising early results for CPI-006 in COVID-19, with plans for a larger trial by year-end. The co-founding of Angel Pharmaceuticals will enhance global pipeline development.
Corvus Pharmaceuticals (NASDAQ: CRVS) is set to present updated data from its Phase 1 study of CPI-006, an immunotherapy for COVID-19, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 9-14, 2020. A poster on the study will be available during the event, highlighting CPI-006's ability to stimulate anti-SARS-CoV-2 antibody responses.
The company will also host an R&D Symposium webcast on November 12, 2020, showcasing COVID-19 program data and advancements in its cancer portfolio.
Corvus Pharmaceuticals announced a strategic collaboration with Angel Pharmaceuticals, securing a 49.7% equity stake to enhance its oncology pipeline development in China. Angel, a new biopharmaceutical company, aims to address serious diseases and launches with a $41 million financing, valuing it at $106 million. The collaboration allows for the development of three clinical-stage candidates and global BTK inhibitor programs. Clinical trials for these candidates are expected to commence within 12 to 18 months, leveraging a partnership with prominent Chinese investors and a talented local team.
Corvus Pharmaceuticals (CRVS) announced the completion of enrollment for the first three cohorts of its Phase 1 study for CPI-006, a novel immunotherapy targeting COVID-19. The data indicates a dose-response effect with prolonged high titers of SARS-CoV-2 specific antibodies at 56 days in the 1.0 mg/kg cohort. All treated patients showed increased memory B and T cells, and no drug-related safety issues were reported. Final cohort enrollment is underway, and a pivotal study is planned by year-end. Results are expected at the upcoming SITC meeting in November.
Corvus Pharmaceuticals (CRVS) announced new data from its collaboration with Genentech during the ESMO Virtual Congress 2020. The data focuses on ciforadenant combined with atezolizumab for treating non-small cell lung cancer (NSCLC). In a small study, patients showed longer disease control and overall survival compared to chemotherapy. The median overall survival was 11.5 months for the combination group versus 9.4 months for chemotherapy. Safety data indicated fewer adverse events. Corvus aims to advance ciforadenant into pivotal studies for advanced refractory renal cell cancer.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced promising results from its Phase 1 study of CPI-006 as an immunotherapy for COVID-19. Patients in the first two cohorts exhibited significant antibody responses within 7 days, with neutralizing antibody levels rising to >1:200,000 by day 28. All treated patients showed clinical improvement and were discharged without safety issues. The study has enrolled 30 patients, with plans for an FDA meeting to discuss future pivotal studies. CPI-006 aims to activate the immune system potentially offering long-term immunity against SARS-CoV-2.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation in two upcoming investor conferences. The company will present at the HC Wainwright 22nd Annual Investment Conference on September 14, 2020, at 4:00 PM ET, and at the Cantor Virtual Healthcare Conference on September 17, 2020, at 4:40 PM ET. Both presentations will be available via webcast for 90 days on the Corvus website. Corvus is focused on developing innovative therapies for cancer and is currently advancing multiple clinical trials.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11 from 2:55-3:25pm ET. A live webcast will be available for 90 days post-event via the Corvus website.
The company is focused on innovative cancer treatments, studying lead candidates CPI-444 and CPI-006 in various clinical trials. Their research also explores CPI-818 for T-cell lymphomas and CPI-006 for COVID-19.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported its Q2 2020 financial results, highlighting progress in its oncology programs, particularly ciforadenant, which showed a 17% objective response rate in a subset of renal cell carcinoma patients. The company plans to discuss a pivotal study with the FDA. Additionally, they initiated a Phase 1 study for CPI-006 targeting COVID-19, with early results indicating a favorable antibody response. Financially, Corvus ended Q2 with $59.3 million in cash, down from $78.0 million at year-end 2019, and reported a net loss of $10.6 million, an improvement from $13.0 million in Q2 2019.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced a conference call on July 30, 2020, at 4:30 pm ET to discuss its business update and second quarter 2020 financial results. The call can be accessed via a toll-free number or by webcast through the investor relations section of their website. Corvus is a clinical-stage biopharmaceutical firm focused on cancer therapies, with key products including ciforadenant, CPI-006, and CPI-818 currently in various clinical trials, including studies for COVID-19 treatment.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
